Thierry Passeron: Efficacy of Ruxolitinib Cream by Body Region in Vitiligo – A Pooled Analysis of the TRuE-V Phase 3 Studies

Touch Medical Media coverage of data presented at EADV 2022:

TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies investigating ruxolitinib cream in adults and adolescents with vitiligo. touchIMMUNOLOGY were delighted to speak with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the rationale and findings from his pooled analysis looking at the effect of ruxolitinib cream on achievement of VASI50 by body region.

The abstract ‘Effect of Ruxolitinib Cream on Achievement of VASI50 by Body Region: Week 52 Pooled Analysis of the TRuE-V Phase 3 Studies.‘ (Abstract number: 3640) was presented at EADV 2022, 7-10 September, 2022.

Questions

1. Could you give us a brief overview of the clinical development of ruxolitinib cream which has led to its approval for the treatment of vitiligo? (0:11)
2. What have been the efficacy and safety findings of the TRuE-V studies, and how clinically meaningful are these findings? (0:52)
3. What was the rationale for the pooled analysis you are presenting? (1:45)
4. What were the findings of this analysis and what are the implications of these findings? (2:38)
5. What has been the clinical impact of ruxolitinib cream in this indication since its approval? (3:27)

Disclosures: Thierry Passeron discloses consulting for Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, and UCB pharma; receiving grant/ research support from Abbvie, Almirall, BMS, Celgene, Incyte, Isocell, LEO Pharma, and Lilly; and receiving honoraria from Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, and UCB pharma.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.